Haleon plc (NYSE:HLN) Stock Position Cut by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC trimmed its stake in shares of Haleon plc (NYSE:HLN) by 3.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 331,053 shares of the company’s stock after selling 11,557 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Haleon were worth $3,158,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in HLN. Lake Street Advisors Group LLC raised its holdings in Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after purchasing an additional 1,143 shares in the last quarter. Synovus Financial Corp increased its position in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock valued at $1,575,000 after purchasing an additional 1,216 shares during the period. Hexagon Capital Partners LLC raised its stake in shares of Haleon by 18.5% in the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock worth $84,000 after buying an additional 1,238 shares in the last quarter. Peapack Gladstone Financial Corp lifted its holdings in shares of Haleon by 3.2% in the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after buying an additional 1,390 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Haleon by 12.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 13,281 shares of the company’s stock valued at $110,000 after buying an additional 1,450 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Down 0.2 %

Shares of NYSE HLN opened at $9.53 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a market cap of $43.12 billion, a price-to-earnings ratio of 28.01, a P/E/G ratio of 2.60 and a beta of 0.29. The business has a fifty day simple moving average of $9.54 and a 200-day simple moving average of $9.75.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.74 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. During the same period in the prior year, the firm earned $0.10 earnings per share. Sell-side analysts predict that Haleon plc will post 0.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.